FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313259632> ?p ?o ?g. }

• W4313259632 endingPage "74" @default.
• W4313259632 startingPage "74" @default.
• W4313259632 abstract "Till date, different types of conventional drugs have been used to fight tumors. However, they have significant flaws, including their usage being constrained because of their low bioavailability, poor supply, and serious side effects. The modern combination therapy has been viewed as a potent strategy for treating serious illnesses, including cancer-type feared diseases. The nanoparticles are a promising choice for cancer therapeutic and diagnostic applications because of their fascinating optoelectronic and physicochemical features. Among the metallic nanoparticles, Zinc oxide nanoparticles possess interesting physicochemical and anti-cancer characteristics, such as ROS generation, high retention, enhanced permeability etc., making them attractive candidates for the treatment and diagnosis of cancer. Zinc oxide nanoparticles showed anti-cancer property via excessive reactive oxygen species (ROS) production, and by the destruction of mitochondrial membrane. Here, we have synthesized organic/inorganic hybrid nanosystem composed of chymotrypsin protein (Chymo) with AzureC (AzC) conjugated with Zinc oxide nanoparticles (ZnONPs). The conjugation of AzureC with ZnONPs was confirmed by transmission electron microscopy (TEM), zeta potential, and dynamic light scattering (DLS) experiment. The interaction of Chymo with AzC alone and AzC-ZnONPs was investigated, and it was observed that the interaction was enhanced in the presence of ZnONPs, which was concluded by the results obtained from different spectroscopic techniques such as UV-Visible spectroscopy, fluorescence spectroscopy and circular dichroism in combination with molecular docking. UV-Visible spectroscopic studies and the corresponding binding parameters showed that the binding of AzC-ZnONPs complex with Chymo is much higher than that of AzC alone. Moreover, the fluorescence measurement showed enhancement in static quenching during titration of Chymo with AzC-ZnONPs as compared to dye alone. In addition to this, circular dichroism results show that the dye and dye-NPs conjugate do not cause much structural change in α-Chymo. The molecular docking and thermodynamic studies showed the predominance of hydrogen bonding, Van der Waal force, and hydrophobic forces during the interactions. After correlation of all the data, interaction of Chymo with AzC-ZnONPs complex showed strong interaction as compared to dye alone. The moderate binding with chymo without any alteration in the structure makes it desirable for the distribution and pharmacokinetics. In addition, the in vitro cytotoxicity of the AzC-ZnONPs was demonstrated on A-549 adenocarcinoma cell line. Our findings from physiochemical investigations suggested that the chymotrypsin coated AzC conjugated ZnONPs could be used as the novel nanoconjugates for various cancer phototherapies." @default.
• W4313259632 created "2023-01-06" @default.
• W4313259632 creator A5054673279 @default.
• W4313259632 creator A5064101907 @default.
• W4313259632 creator A5065641107 @default.
• W4313259632 creator A5080932120 @default.
• W4313259632 date "2022-12-26" @default.
• W4313259632 modified "2023-10-14" @default.
• W4313259632 title "Influence of Green Synthesized Zinc Oxide Nanoparticles on Molecular Interaction and Comparative Binding of Azure Dye with Chymotrypsin: Novel Nano-Conjugate for Cancer Phototherapy" @default.
• W4313259632 cites W1606166973 @default.
• W4313259632 cites W1831206839 @default.
• W4313259632 cites W1964789744 @default.
• W4313259632 cites W1968024670 @default.
• W4313259632 cites W1972077559 @default.
• W4313259632 cites W1988497535 @default.
• W4313259632 cites W1990456103 @default.
• W4313259632 cites W1995235292 @default.
• W4313259632 cites W1997153101 @default.
• W4313259632 cites W1997758039 @default.
• W4313259632 cites W1999248402 @default.
• W4313259632 cites W2002420277 @default.
• W4313259632 cites W2012748063 @default.
• W4313259632 cites W2018853214 @default.
• W4313259632 cites W2020264299 @default.
• W4313259632 cites W2048093888 @default.
• W4313259632 cites W2051504973 @default.
• W4313259632 cites W2052750265 @default.
• W4313259632 cites W2057910069 @default.
• W4313259632 cites W2073932571 @default.
• W4313259632 cites W2077389111 @default.
• W4313259632 cites W2078144770 @default.
• W4313259632 cites W2081813564 @default.
• W4313259632 cites W2087955709 @default.
• W4313259632 cites W2158685498 @default.
• W4313259632 cites W2292125391 @default.
• W4313259632 cites W2301727737 @default.
• W4313259632 cites W2487249511 @default.
• W4313259632 cites W2565316838 @default.
• W4313259632 cites W2579228029 @default.
• W4313259632 cites W2616724130 @default.
• W4313259632 cites W2793986432 @default.
• W4313259632 cites W2794599464 @default.
• W4313259632 cites W2803279238 @default.
• W4313259632 cites W2920894319 @default.
• W4313259632 cites W2994778290 @default.
• W4313259632 cites W3003272029 @default.
• W4313259632 cites W3108668810 @default.
• W4313259632 cites W3175373190 @default.
• W4313259632 cites W3176236709 @default.
• W4313259632 cites W3177148970 @default.
• W4313259632 cites W4200014698 @default.
• W4313259632 cites W4205364997 @default.
• W4313259632 cites W4206907499 @default.
• W4313259632 cites W4283313052 @default.
• W4313259632 cites W4296466900 @default.
• W4313259632 cites W4296691830 @default.
• W4313259632 doi "https://doi.org/10.3390/pharmaceutics15010074" @default.
• W4313259632 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36678703" @default.
• W4313259632 hasPublicationYear "2022" @default.
• W4313259632 type Work @default.
• W4313259632 citedByCount "2" @default.
• W4313259632 countsByYear W43132596322023 @default.
• W4313259632 crossrefType "journal-article" @default.
• W4313259632 hasAuthorship W4313259632A5054673279 @default.
• W4313259632 hasAuthorship W4313259632A5064101907 @default.
• W4313259632 hasAuthorship W4313259632A5065641107 @default.
• W4313259632 hasAuthorship W4313259632A5080932120 @default.
• W4313259632 hasBestOaLocation W43132596321 @default.
• W4313259632 hasConcept C112613896 @default.
• W4313259632 hasConcept C121608353 @default.
• W4313259632 hasConcept C12554922 @default.
• W4313259632 hasConcept C126322002 @default.
• W4313259632 hasConcept C133571119 @default.
• W4313259632 hasConcept C134306372 @default.
• W4313259632 hasConcept C13965031 @default.
• W4313259632 hasConcept C14631669 @default.
• W4313259632 hasConcept C155672457 @default.
• W4313259632 hasConcept C171250308 @default.
• W4313259632 hasConcept C178790620 @default.
• W4313259632 hasConcept C185592680 @default.
• W4313259632 hasConcept C192562407 @default.
• W4313259632 hasConcept C197336794 @default.
• W4313259632 hasConcept C21951064 @default.
• W4313259632 hasConcept C2777516457 @default.
• W4313259632 hasConcept C33923547 @default.
• W4313259632 hasConcept C521977710 @default.
• W4313259632 hasConcept C535196362 @default.
• W4313259632 hasConcept C540031477 @default.
• W4313259632 hasConcept C71240020 @default.
• W4313259632 hasConcept C71924100 @default.
• W4313259632 hasConcept C86181022 @default.
• W4313259632 hasConcept C86803240 @default.
• W4313259632 hasConcept C96232424 @default.
• W4313259632 hasConceptScore W4313259632C112613896 @default.
• W4313259632 hasConceptScore W4313259632C121608353 @default.
• W4313259632 hasConceptScore W4313259632C12554922 @default.
• W4313259632 hasConceptScore W4313259632C126322002 @default.
• W4313259632 hasConceptScore W4313259632C133571119 @default.

• next